Company profile: ProciseDx
1.1 - Company Overview
Company description
- Provider of point-of-care diagnostic solutions for physician offices, retail clinics, and urgent care, delivering rapid, lab-quality results. Offerings include tests for infliximab (Procise IFX), adalimumab (Procise ADL), C-reactive protein (Procise CRP), fecal calprotectin (Procise FCP), and the ProciseDx Instrument for quantitative immunoassays.
Products and services
- ProciseDx Instrument: A quantitative immunoassay-optimized diagnostic platform engineered for multi-specimen compatibility (finger prick blood, stool), producing rapid results at the point of care
- Procise IFX: A point-of-care assay that quantifies infliximab levels from a finger prick blood sample, delivering results in under five minutes to support immediate therapeutic monitoring
- Procise ADL: A fingerstick-based assay that measures adalimumab concentrations from a finger prick blood sample, producing results in less than five minutes for on-the-spot drug level assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProciseDx
IDL Biotech
HQ: Sweden
Website
- Description: Provider of in vitro diagnostic (IVD) tests for the healthcare sector, developing, producing, and marketing worldwide. Active in oncology and bacteriology through manufacturing various tumor markers and a rapid Salmonella typhoid test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDL Biotech company profile →
Diagnostic Products
HQ: United States
Website
- Description: Provider of in vitro diagnostics, including the IMMULITE(R) series of immunoassay systems, more than 75 immunoassays, and an expanding menu of essential specific allergens and allergy panels that are run just like other immunoassays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Products company profile →
Immunostics
HQ: United States
Website
- Description: Provider of diagnostic solutions that assist in disease diagnosis, offering a compact automatic immunoassay analyzer, hemochroma PLUS hemoglobin/hematocrit device, hema-screen SPECIFIC GOLD colorectal cancer screening test, Swab-N-Go Home Test COVID-19 Ag with RAPIDCHECK app, Detector UA urine analysis strips, and Detector Strep A rapid test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunostics company profile →
Orion Diagnostica
HQ: Finland
Website
- Description: Provider of clinical diagnostic and hygiene monitoring test systems for healthcare professionals, developing, manufacturing and marketing accurate, affordable tests that are easy to use and deliver fast results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orion Diagnostica company profile →
BioCheck
HQ: United States
Website
- Description: Provider of immunodiagnostic test kits and research reagents, and enzyme immunoassay research services and products, offering immunoassay kits for classifications including cardiac markers and tumor classifications; developed, manufactured, and distributed for worldwide healthcare markets, operating an FDA-certified cGMP device-manufacturing facility in Foster City, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCheck company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProciseDx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProciseDx
2.2 - Growth funds investing in similar companies to ProciseDx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProciseDx
4.2 - Public trading comparable groups for ProciseDx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →